Incannex Healthcare Inc. (IXHL) company profile
Close on Nov 17, 2026Market cap $21.83MP/E –Yield –
About Incannex Healthcare
Pharmaceutical Preparations, SIC 2834
Incannex is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious, chronic conditions. Its pipeline includes IHL-42X, an oral combination therapy in clinical development for obstructive sleep apnea, and PSX-001, a synthetic psilocybin treatment administered alongside psychotherapy for generalized anxiety disorder. The company is also evaluating IHL-675A, an oral combination targeting inflammatory conditions including rheumatoid arthritis. These investigational programs aim to provide alternative pharmacological treatments for patients who are underserved by existing care options.
The company operates clinical trials across sites in the United States and has conducted early-stage studies and collaborative research in Australia. It also participates in a joint venture operating a psychedelic-assisted therapies services clinic in Melbourne, Australia. The provided text mentions manufacturing partnerships in the United States but does not identify the location of the corporate headquarters.
Summary of the business section of Incannex Healthcare's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Incannex Healthcare Inc.
- Headquarters
- Norwest Nsw, Australia
- Address
- 8 Century Circuit, Ste. 105
- Phone
- 61 409 840 786
- Website
- incannex.com
- Employees
- 12, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- GRANT THORNTON AUDIT PTY LTD, Perth, Australia
Stock & identifiers
- Ticker
- IXHL
- Exchange
- Nasdaq
- IPO date
- Mar 2, 2022
- Shares outstanding
- 13M, Sep 24, 2026
- Public float
- $123.50M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Feb 27, 2026
- SEC CIK
- 1873875
- CUSIP
- 45333F208
- ISIN
- US45333F2083
- FIGI
- BBG01J0814Y2
- Share class FIGI
- BBG01J0814Z1
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joel Latham | CEO and President, Director | 24,186,177 |
| Joseph Swan | CFO, Treasurer and Secretary | 921,358 |
| George Anastassov | Director | 2,456,677 |
| Troy Valentine | Director | 12,339,120 |
| Peter Widdows | Director | 1,957,803 |
| Robert Clark | Director | 1,786,956 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Joel Latham Chief Executive Officer | $656.46K | $297.69K | – | $173.59K | $1.13M | -82% |
| Joseph Swan Chief Financial Officer | $150.65K | $30.13K | – | $20.41K | $201.19K | -24% |
| Luigi M. Barbato Chief Medical Officer | $264.06K | – | $233.10K | – | $497.17K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had twelve full-time employees, including eight in R&D and four in general management and administration.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 17, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 22, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 13, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 25, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 10, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 15, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 29, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 29, 2023 | Deregistration | Termination of SEC registration (Form 15) |
| Nov 29, 2023 | Name change | Name changed from Incannex Healthcare Ltd to Incannex Healthcare Inc. |
| Nov 28, 2023 | Delisting | Notice of delisting from exchange (Form 25) |
| Nov 30, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?